ISN Journal summaries on sodium-glucose cotransporter-2 inhibitors and CKD in indigenous populations in Kerala
Kidney International®
There are currently no approved therapies to slow chronic kidney disease (CKD) progression across the diverse causes of pediatric CKD, despite evidence that sodium–glucose cotransporter-2 inhibitors (SGLT2is) slow kidney disease progression in adults.
A July 2023 multi-stakeholder workshop examined the feasibility, challenges, and regulatory pathways for evaluating SGLT2is in pediatric CKD, including the potential for extrapolating adult trial data.
The discussions helped define a viable development pathway and contributed to a subsequent US FDA requirement for pediatric studies of empagliflozin.
Kidney International Reports®
Chronic kidney disease in indigenous populations in Kerala, India
Data on chronic kidney disease (CKD) in Indigenous populations in India are limited.
In a community-based study of 2,029 tribal adults in Kerala, CKD prevalence was 22.6%, with most cases detected at early stages and higher prevalence among women.
The findings point to a substantial hidden burden of CKD and the need for equity-focused, culturally appropriate screening and prevention strategies.
